{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T23:56:56Z","timestamp":1782863816251,"version":"3.54.5"},"reference-count":73,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.cmi.2024.06.020","type":"journal-article","created":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T03:23:48Z","timestamp":1719545028000},"page":"49-56","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Advances and prospect in herpesviruses infections after haematopoietic cell transplantation: closer to the finish line?"],"prefix":"10.1016","volume":"31","author":[{"given":"Joseph","family":"Sassine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily A.","family":"Siegrist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tali Fainguelernt","family":"Shafat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy F.","family":"Chemaly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2024.06.020_bib1","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1182\/blood-2016-10-748426","article-title":"The cumulative burden of double-stranded DNA virus detection after allogeneic HCT is associated with increased mortality","volume":"129","author":"Hill","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.cmi.2024.06.020_bib2","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.bbmt.2009.06.019","article-title":"Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective","volume":"15","author":"Tomblyn","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.cmi.2024.06.020_bib3","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.hoc.2010.11.011","article-title":"Cytomegalovirus in hematopoietic stem cell transplant recipients","volume":"25","author":"Ljungman","year":"2011","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.cmi.2024.06.020_bib4","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.jtct.2021.05.001","article-title":"American society for transplantation and cellular therapy series: #3-Prevention of cytomegalovirus infection and disease after hematopoietic cell transplantation","volume":"27","author":"Hakki","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.cmi.2024.06.020_bib5","doi-asserted-by":"crossref","first-page":"e260","DOI":"10.1016\/S1473-3099(19)30107-0","article-title":"Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7)","volume":"19","author":"Ljungman","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2024.06.020_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2013.09.004","article-title":"Cytomegalovirus diseases after hematopoietic stem cell transplantation: a mini-review","volume":"342","author":"Ariza-Heredia","year":"2014","journal-title":"Cancer Lett"},{"key":"10.1016\/j.cmi.2024.06.020_bib7","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1097\/QCO.0000000000000983","article-title":"A\u00a0new direction for cytomegalovirus prophylaxis among transplant recipients: benefits and nonviral outcomes of letermovir use as primary CMV prophylaxis","volume":"36","author":"Moore","year":"2023","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.cmi.2024.06.020_bib8","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1093\/cid\/ciab298","article-title":"Refractory and resistant cytomegalovirus after hematopoietic cell transplant in the letermovir primary prophylaxis era","volume":"73","author":"Sassine","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2024.06.020_bib9","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1093\/ofid\/ofac492.112","article-title":"Long term hematopoietic cell transplant outcomes in patients at high risk for cytomegalovirus infections in the era of letermovir","volume":"9","author":"Febres-Aldana","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.cmi.2024.06.020_bib10","doi-asserted-by":"crossref","first-page":"e119","DOI":"10.1016\/S2352-3026(15)00289-6","article-title":"Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: A retrospective cohort study","volume":"3","author":"Green","year":"2016","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.cmi.2024.06.020_bib11","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1128\/AAC.01596-09","article-title":"In\u00a0vitro and in\u00a0vivo activities of the novel anticytomegalovirus compound AIC246","volume":"54","author":"Lischka","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2024.06.020_bib12","doi-asserted-by":"crossref","first-page":"13614","DOI":"10.1021\/acs.jmedchem.2c00668","article-title":"Discovery, chemistry, and preclinical development of pritelivir, a novel\u00a0treatment option for acyclovir-resistant herpes simplex virus infections","volume":"65","author":"Birkmann","year":"2022","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.cmi.2024.06.020_bib13","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1001\/jama.2016.18189","article-title":"Effect of pritelivir compared with valacyclovir on genital HSV-2 shedding in patients with frequent recurrences: a randomized clinical trial","volume":"316","author":"Wald","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.cmi.2024.06.020_bib14","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.antiviral.2019.01.008","article-title":"In\u00a0vitro comparison of currently available and investigational antiviral agents against pathogenic human double-stranded DNA viruses: a systematic literature review","volume":"163","author":"Chemaly","year":"2019","journal-title":"Antivir Res."},{"key":"10.1016\/j.cmi.2024.06.020_bib15","series-title":"Letermovir package insert","year":"2017"},{"key":"10.1016\/j.cmi.2024.06.020_bib16","series-title":"Kucers\u2019 the use of antibiotics","first-page":"3619","article-title":"Letermovir","author":"Aitken","year":"2018"},{"key":"10.1016\/j.cmi.2024.06.020_bib17","series-title":"Maribavir package insert","year":"2021"},{"key":"10.1016\/j.cmi.2024.06.020_bib18","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/cpdd.1241","volume":"12","author":"Kropeit","year":"2023","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.cmi.2024.06.020_bib19","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation","volume":"377","author":"Marty","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2024.06.020_bib20","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofac687","article-title":"Real-world outcomes associated with letermovir use for cytomegalovirus primary prophylaxis in allogeneic hematopoietic cell transplant recipients: a systematic review and meta-analysis of observational studies","volume":"10","author":"Vyas","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.cmi.2024.06.020_bib21","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41409-023-01920-w","article-title":"Cytomegalovirus breakthrough and resistance during letermovir prophylaxis","volume":"58","author":"Perchetti","year":"2023","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.cmi.2024.06.020_bib22","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/S2352-3026(23)00344-7","article-title":"Efficacy and safety of extended duration letermovir prophylaxis in recipients of haematopoietic stem-cell transplantation at risk of cytomegalovirus infection: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"11","author":"Russo","year":"2024","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.cmi.2024.06.020_bib23","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1182\/blood.2020009396","article-title":"Cytomegalovirus-specific T-cell reconstitution following letermovir prophylaxis after hematopoietic cell transplantation","volume":"138","author":"Zamora","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.cmi.2024.06.020_bib24","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.cmi.2024.03.001","article-title":"Mortality in recipients of allogeneic haematopoietic cell transplantation in the era of cytomegalovirus primary prophylaxis: a single centre retrospective experience","volume":"30","author":"Febres-Aldana","year":"2024","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2024.06.020_bib25","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1093\/cid\/ciab1064","article-title":"Impact of letermovir primary cytomegalovirus prophylaxis on 1-year mortality after allogeneic hematopoietic cell transplantation: A retrospective cohort study","volume":"75","author":"Su","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2024.06.020_bib26","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1182\/blood-2016-06-688432","article-title":"How I treat resistant cytomegalovirus infection in hematopoietic cell transplantation recipients","volume":"128","author":"El Chaer","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.cmi.2024.06.020_bib27","doi-asserted-by":"crossref","DOI":"10.1128\/aac.02405-21","article-title":"New perspectives on antimicrobial agents: maribavir","volume":"66","author":"Halpern-Cohen","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2024.06.020_bib28","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1093\/cid\/ciab988","article-title":"Maribavir for refractory cytomegalovirus infections with or without\u00a0resistance post-transplant: results from a phase 3 randomized clinical\u00a0trial","volume":"75","author":"Avery","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2024.06.020_bib29","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1093\/infdis\/jiad293","article-title":"Drug resistance assessed in a phase 3 clinical trial of maribavir therapy for refractory or resistant cytomegalovirus infection in transplant recipients","volume":"229","author":"Chou","year":"2024","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.cmi.2024.06.020_bib30","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1093\/cid\/ciad709","article-title":"Treatment for first cytomegalovirus infection post-hematopoietic cell transplant in the AURORA trial: a multicenter, double-blind, randomized, phase 3 trial comparing maribavir with valganciclovir","volume":"78","author":"Papanicolaou","year":"2024","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2024.06.020_bib31","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1093\/cid\/ciz1210","article-title":"Cytomegalovirus (CMV) cell-mediated immunity and cmv infection after allogeneic hematopoietic cell transplantation: the REACT Study","volume":"71","author":"Chemaly","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2024.06.020_bib32","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofad386","article-title":"Impact of baseline and week 2 and week 4 posttransplant CMV cell-mediated immunity on risk of CMV infections and mortality in recipients of allogeneic hematopoietic cell transplant","volume":"10","author":"Ariza-Heredia","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.cmi.2024.06.020_bib33","doi-asserted-by":"crossref","first-page":"3745","DOI":"10.1182\/blood-2012-08-448977","article-title":"Donor-derived CMV-specific T cells reduce the requirement for CMV-directed pharmacotherapy after allogeneic stem cell transplantation","volume":"121","author":"Blyth","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.cmi.2024.06.020_bib34","doi-asserted-by":"crossref","first-page":"4949","DOI":"10.1182\/bloodadvances.2022007103","article-title":"Third-party CMV- and EBV-specific T-cells for first viral reactivation after allogeneic stem cell transplant","volume":"6","author":"Jiang","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.cmi.2024.06.020_bib35","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1158\/1078-0432.CCR-22-2415","article-title":"Posoleucel, an allogeneic, off-the-shelf multivirus-specific T-cell therapy, for the treatment of refractory viral infections in the post-HCT setting","volume":"29","author":"Pfeiffer","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cmi.2024.06.020_bib36","series-title":"AlloVir provides updates on phase 3 clinical development program for posoleucel, an allogeneic virus-specific T cell therapy [Internet]","author":"AlloVir","year":"2023"},{"key":"10.1016\/j.cmi.2024.06.020_bib37","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1007\/s00277-016-2711-1","article-title":"Infectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis strategy guidelines 2016","volume":"95","author":"Ullmann","year":"2016","journal-title":"Ann Hematol"},{"key":"10.1016\/j.cmi.2024.06.020_bib38","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/bmt.2008.386","article-title":"Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the second European conference on infections in leukemia","volume":"43","author":"Styczynski","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.cmi.2024.06.020_bib39","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1093\/infdis\/jix042","article-title":"Association of the emergence of acyclovir-resistant herpes simplex virus type 1 with prognosis in hematopoietic stem cell transplantation patients","volume":"215","author":"Kakiuchi","year":"2017","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.cmi.2024.06.020_bib40","series-title":"Mandell, douglas, and bennett\u2019s principles and practice of infectious diseases","first-page":"1828","article-title":"Herpes simplex virus","author":"Schiffer","year":"2020"},{"key":"10.1016\/j.cmi.2024.06.020_bib41","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/tri.13142","article-title":"Delay of alternative antiviral therapy and poor outcomes of acyclovir-resistant herpes simplex virus infections in recipients of allogeneic stem cell transplant - a retrospective study","volume":"31","author":"Ariza-Heredia","year":"2018","journal-title":"Transpl Int"},{"key":"10.1016\/j.cmi.2024.06.020_bib42","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.antiviral.2008.04.005","article-title":"Mutations close to functional motif IV in HSV-1 UL5 helicase that confer resistance to HSV helicase-primase inhibitors, variously affect virus growth rate and pathogenicity","volume":"80","author":"Biswas","year":"2008","journal-title":"Antivir Res."},{"key":"10.1016\/j.cmi.2024.06.020_bib43","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1093\/jac\/dkac165","article-title":"Pritelivir for recurrent aciclovir-resistant herpes simplex virus 2 infections in immunocompromised patients","volume":"77","author":"Serris","year":"2022","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2024.06.020_bib44","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01732-22","article-title":"Salvage treatment of refractory HSV oral lesions with pritelivir in allogeneic hematopoietic cell transplant recipients","volume":"67","author":"Bosetti","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2024.06.020_bib45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2017.11.002","article-title":"Efficacy of pritelivir and acyclovir in the treatment of herpes simplex virus infections in a mouse model of herpes simplex encephalitis","volume":"149","author":"Quenelle","year":"2018","journal-title":"Antivir Res."},{"key":"10.1016\/j.cmi.2024.06.020_bib46","series-title":"Mandell, douglas, and bennett\u2019s principles and practice of infectious diseases","first-page":"1849","article-title":"Chickenpox and herpes zoster (varicella-zoster virus)","author":"Whitley","year":"2020"},{"key":"10.1016\/j.cmi.2024.06.020_bib47","first-page":"2062","article-title":"How I prevent viral reactivation in high-risk patients","volume":"141","author":"Dadwal","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.cmi.2024.06.020_bib48","series-title":"Clinical considerations for use of recombinant zoster vaccine (RZV, Shingrix) in immunocompromised adults aged \u226519 years","author":"Centers for Disease Control and Prevention","year":"2022"},{"key":"10.1016\/j.cmi.2024.06.020_bib49","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1001\/jama.2019.9053","article-title":"Effect of recombinant zoster vaccine on incidence of herpes zoster after autologous stem cell transplantation: a randomized clinical trial","volume":"322","author":"Bastidas","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.cmi.2024.06.020_bib50","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1182\/bloodadvances.2020003749","article-title":"Safety and reactogenicity of the recombinant zoster vaccine after allogeneic hematopoietic cell transplantation","volume":"5","author":"Baumrin","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.cmi.2024.06.020_bib51","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1056\/NEJMra1702693","article-title":"Post-transplantation lymphoproliferative disorders in adults","volume":"378","author":"Dierickx","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2024.06.020_bib52","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1182\/blood.V98.4.972","article-title":"Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell\u2013depleted SCT","volume":"98","author":"van Esser","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.cmi.2024.06.020_bib53","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/bmt.2011.28","article-title":"In\u00a0vivo B-cell depletion with rituximab for alternative donor hemopoietic SCT","volume":"47","author":"Dominietto","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.cmi.2024.06.020_bib54","doi-asserted-by":"crossref","first-page":"4364","DOI":"10.1182\/blood.V99.12.4364","article-title":"Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation","volume":"99","author":"van Esser","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.cmi.2024.06.020_bib55","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/s41409-019-0699-6","article-title":"Pre-emptive rituximab treatment for Epstein-Barr virus reactivation after allogeneic hematopoietic stem cell transplantation is a worthwhile strategy in high-risk recipients: a comparative study for immune recovery and clinical outcomes","volume":"55","author":"Stocker","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.cmi.2024.06.020_bib56","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1097\/TP.0b013e3182664042","article-title":"Increased infection rate after preemptive rituximab treatment for Epstein-Barr virus reactivation after allogeneic hematopoietic stem-cell transplantation","volume":"94","author":"Petropoulou","year":"2012","journal-title":"Transplantation"},{"key":"10.1016\/j.cmi.2024.06.020_bib57","doi-asserted-by":"crossref","first-page":"803","DOI":"10.3324\/haematol.2016.144428","article-title":"Management of Epstein-Barr virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: sixth European Conference on Infections in Leukemia (ECIL-6) guidelines","volume":"101","author":"Styczynski","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.cmi.2024.06.020_bib58","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood-2009-08-239186","article-title":"Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients","volume":"115","author":"Heslop","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.cmi.2024.06.020_bib59","doi-asserted-by":"crossref","first-page":"5113","DOI":"10.1182\/blood-2013-02-486324","article-title":"Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation","volume":"121","author":"Leen","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.cmi.2024.06.020_bib60","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/S1470-2045(23)00649-6","volume":"25","author":"Mahadeo","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cmi.2024.06.020_bib61","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/j.bbmt.2012.05.012","article-title":"HHV-6 reactivation and associated sequelae after hematopoietic cell transplantation","volume":"18","author":"Zerr","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.cmi.2024.06.020_bib62","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/cid\/cix804","article-title":"Kinetics of double-stranded DNA viremia after allogeneic hematopoietic cell transplantation","volume":"66","author":"Hill","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2024.06.020_bib63","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofac398","article-title":"Current role of prospective monitoring and preemptive and prophylactic therapy for human herpesvirus 6 after allogeneic stem cell transplantation","volume":"9","author":"Handley","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.cmi.2024.06.020_bib64","doi-asserted-by":"crossref","first-page":"1450.e1","DOI":"10.1016\/j.cmi.2023.07.026","article-title":"Human herpesvirus-6 reactivation and disease after allogeneic haematopoietic cell transplantation in the era of letermovir for cytomegalovirus prophylaxis","volume":"29","author":"Kampouri","year":"2023","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2024.06.020_bib65","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/j.bbmt.2012.04.016","article-title":"Cord-blood hematopoietic stem cell transplant confers an increased risk for human herpesvirus-6-associated acute limbic encephalitis: A cohort analysis","volume":"18","author":"Hill","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.cmi.2024.06.020_bib66","first-page":"176","article-title":"Current understanding of human herpesvirus 6 (HHV-6) chromosomal integration","volume":"104720","author":"Aimola","year":"2020","journal-title":"Antivir Res."},{"key":"10.1016\/j.cmi.2024.06.020_bib67","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.3324\/haematol.2019.223073","article-title":"Guidelines from the 2017 European Conference on Infections in Leukaemia for management of HHV-6 infection in patients with hematologic malignancies and after hematopoietic stem cell transplantation","volume":"104","author":"Ward","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.cmi.2024.06.020_bib68","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/cid\/cit358","article-title":"Human herpesvirus 6 (HHV-6) reactivation and HHV-6 encephalitis after allogeneic hematopoietic cell transplantation: a multicenter, prospective study","volume":"57","author":"Ogata","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2024.06.020_bib69","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1016\/j.bbmt.2018.02.008","article-title":"Effects of prophylactic foscarnet on human herpesvirus-6 reactivation and encephalitis in cord blood transplant recipients: a prospective multicenter trial with an historical control group","volume":"24","author":"Ogata","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.cmi.2024.06.020_bib70","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.jcv.2014.07.001","article-title":"Human herpesvirus 6 can be detected in cerebrospinal fluid without associated symptoms after allogeneic hematopoietic cell transplantation","volume":"61","author":"Hill","year":"2014","journal-title":"J\u00a0Clin Virol"},{"key":"10.1016\/j.cmi.2024.06.020_bib71","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.bbmt.2014.02.010","article-title":"Frequent human herpesvirus-6 viremia but low incidence of encephalitis in double-unit cord blood recipients transplanted without antithymocyte globulin","volume":"20","author":"Olson","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.cmi.2024.06.020_bib72","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/bmt.2012.121","article-title":"Foscarnet against human herpesvirus (HHV)-6 reactivation after allo-SCT: breakthrough HHV-6 encephalitis following antiviral prophylaxis","volume":"48","author":"Ogata","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.cmi.2024.06.020_bib73","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/s41467-024-44828-9","article-title":"HHV-6B detection and host gene expression implicate HHV-6B as pulmonary pathogen after hematopoietic cell transplant","volume":"15","author":"Hill","year":"2024","journal-title":"Nat Commun"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X24003008?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X24003008?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T04:10:14Z","timestamp":1767240614000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X24003008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":73,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S1198743X24003008"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2024.06.020","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances and prospect in herpesviruses infections after haematopoietic cell transplantation: closer to the finish line?","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2024.06.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}